August 30, 2017 -Why wouldn’t you want to be 100% certain about bacterial presence?
Standard Imaging Mode™ Fluorescence Imaging Mode™
In the recent publication in the Journal of Wound Care ‘Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study’1,… Read More
August 2, 2017 -
Journal: Journal of Wound Care.
Authors: Monique Y. Rennie, PhD; Liis Lindvere-Teene, MSc; Kim Tapang, MD; Ron Linden, MD
MolecuLight Inc., Toronto, ON, Canada; Judy Dan Research and Treatment Centre, Ontario; Wound Care Inc., North York, ON, Canada.
Objective: Bacteria in chronic wounds are invisible to the
… Read MoreAugust 2, 2017 -The FDA-approved skin substitute reduces inflammation and transforms chronic wounds into injuries.
Kerecis Ltd, a small company in Iceland has the only FDA-approved skin substitute derived from fish.
Fertram Sigurjonsson is the Chairman and CEO of Kerecis. His small company has spent the past nine years applying fish skin to
… Read MoreMay 16, 2017 -
An e-poster by Rose Raizman, RN-EC MSc, featuring the MolecuLight i:X, presented at the recent EWMA conference in Amsterdam, has been selected to receive one of the four e-poster prizes awarded from this year’s meeting. Her study, entitled “Real-time fluorescence imaging of bacteria guides treatment selection and timing of dressing changes
… Read MoreMay 12, 2017 -Antibiotic resistance – an urgent issue of global concern
Antibiotic resistance is an urgent issue of global concern, and this growing epidemic is directly related to the level of antibiotic use. A key contributing factor to antibiotic misuse in patients with wounds is diagnostic uncertainty, i.e. is there a bacterial
… Read MoreMay 3, 2017 -Change, Opportunities and Challenges – Wound Management in Changing Healthcare Systems
Amsterdam, May 3-6 2017
The theme this year resonated with national healthcare systems in Europe, which are continuously changing, reorganising and adapting to respond to changing demographics and budget restrictions. Technology continues to influence wound care clinicians
… Read MoreApril 24, 2017 -New wave of fluorescence imaging technologies may help in managing infection.
Effective wound management is a challenge for healthcare. In Canada, wounds cost $3.9 billion annually (approximately 3% of total healthcare expenditures). Individuals with chronic wounds experience harmful consequences including intractable pain, infectious complications, hospitalization, reduced quality of life, depression,
… Read MoreApril 21, 2017 -Bacterial infections account for 75% of mortalities in severely burned patients.
The Journal of Burn Care Research recently published an article (April 2017) which highlights MolecuLight i:X’s ability to guide swabbing and debridement, locate regions of concern that otherwise would have been overlooked, target treatments more effectively, and prevent unnecessary prescription
… Read MoreApril 5, 2017 -SAWC Spring in San Diego attracted over 2000 attendees and 200 exhibitors
This year’s SAWC Spring in San Diego attracted over 2000 attendees and 200 exhibitors. Amongst the many great presentations, Dr. Greg Schultz’s and Rosemary Hill’s particularly stood out. Dr Schultz (University of Florida, USA) presented in the Science
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s Technology
Breakthrough Designation
MolecuLight i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2025
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.